Stockscreener 앱 받기
6.80
6.72%
-0.49
전일 마감가:
$7.29
열려 있는:
$7.29
하루 거래량:
7.23M
Relative Volume:
0.95
시가총액:
$2.08B
수익:
$79.21M
순이익/손실:
$-143.96M
주가수익비율:
-14.18
EPS:
-0.4796
순현금흐름:
$-189.60M
1주 성능:
-16.15%
1개월 성능:
+33.60%
6개월 성능:
+55.61%
1년 성능:
+60.00%
1일 변동 폭
$6.6036
$7.29
1주일 범위
$6.6036
$8.44
52주 변동 폭
$2.745
$8.44
앱셀레라바이오로직스 Stock (ABCL) Company Profile
명칭
Abcellera Biologics Inc
전화
(604) 559-9005
주소
150 W 4TH AVENUE, VANCOUVER
Compare ABCL vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
6.80 | 2.08B | 79.21M | -143.96M | -189.60M | -0.4796 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
앱셀레라바이오로직스 Stock (ABCL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-07-07 | 재개 | Leerink Partners | Outperform |
| 2024-08-20 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2024-02-22 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-12-05 | 개시 | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-10-13 | 재개 | Piper Sandler | Overweight |
| 2023-02-28 | 개시 | Cowen | Outperform |
| 2022-12-15 | 개시 | Goldman | Buy |
| 2022-11-16 | 개시 | Truist | Buy |
| 2021-12-21 | 개시 | The Benchmark Company | Buy |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2021-01-05 | 개시 | Berenberg | Buy |
| 2021-01-05 | 개시 | Credit Suisse | Outperform |
| 2021-01-05 | 개시 | SVB Leerink | Outperform |
| 2021-01-05 | 개시 | Stifel | Buy |
모두보기
앱셀레라바이오로직스 주식(ABCL)의 최신 뉴스
Has ABCELLERA BIOLG (ABCL) Outpaced Other Medical Stocks This Year? - MSN
ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains? - MSN
ABCL Stock Clocks Best Week Since February On Clinical Data Anticipation, Baker Bros Stake Boost - Stocktwits
AbCellera Biologics (ABCL) TD Cowen 46th Annual Health Care Conference Summary - Quartr
AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026 - BNN Bloomberg
Are you looking for a top momentum pick? Why AbCellera Biologics Inc. (ABCL) is a great choice - MSN
AbCellera Biologics (ABCL) Q4 2024 earnings summary - Quartr
Press Release: AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026 - Moomoo
AbCellera Appoints Dr. Victor Sandor to its Board of Directors - AOL.com
Are You Looking for a Top Momentum Pick? Why AbCellera Biologics Inc. (ABCL) is a Great Choice - Yahoo Finance
Benchmark Upgrades AbCellera Biologics to Buy From Hold, Price Target Is $11 - Moomoo
AbCellera Biologics Price Target Announced at $11.00/Share by Benchmark - Moomoo
What AbCellera Biologics (ABCL)'s New Oncology Veteran Director Means For Shareholders - simplywall.st
[Form 4] AbCellera Biologics Inc. Insider Trading Activity - Stock Titan
AbCellera (ABCL) director Lynn Seely submits initial Form 3 insider ownership filing - Stock Titan
Lynn Seely appointed to AbCellera Board as Class III director - TradingView
Dr. Lynn Seely joins AbCellera (NASDAQ: ABCL) board as independent director - Stock Titan
AbCellera appoints Lynn Seely to board of directors By Investing.com - Investing.com South Africa
AbCellera appoints Lynn Seely to board of directors - Investing.com
AbCellera Appoints Dr. Lynn Seely to its Board of Directors - Yahoo Finance
Is ABCELLERA BIOLG (ABCL) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
ABCL News | ABCELLERA BIOLOGICS INC (NASDAQ:ABCL) - ChartMill
Is AbCellera Biologics (ABCL) One of the Best Stocks with Biggest Upside? - Yahoo Finance
AbCellera Biologics (ABCL) Could Be 22% Undervalued After Jazz Cancer Partnership - simplywall.st
ABCL Jumps As Jazz Deal Fuels Antibody Pipeline Momentum - StocksToTrade
AbCellera Biologics Stock (ABCL) Opinions on Recent Technical Breakout and Pipeline Progress - Quiver Quantitative
Why Did SLS, MRNA, ABCL Stocks Surge To 52-Week Highs Last Week? - Stocktwits
Is AbCellera (ABCL) Using the Jazz Partnership to Quietly Redefine Its Oncology Platform Strategy? - simplywall.st
Enterprise value to revenue forward of AbCellera Biologics Inc. – NASDAQ:ABCL - TradingView
Enterprise value to EBIT forward of AbCellera Biologics Inc. – NASDAQ:ABCL - TradingView
AbCellera Biologics(ABCL) Stock Options Chain | Quotes & News - Moomoo
Price to sales forward of AbCellera Biologics Inc. – NASDAQ:ABCL - TradingView
Enterprise value to EBITDA forward of AbCellera Biologics Inc. – NASDAQ:ABCL - TradingView
Price to earnings forward of AbCellera Biologics Inc. – NASDAQ:ABCL - TradingView
Price to book forward of AbCellera Biologics Inc. – NASDAQ:ABCL - TradingView
JonesTrading Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Abcellera Biologics stock hits 52-week high at 6.79 USD By Investing.com - Investing.com Nigeria
ABCL Stock Pops As Jazz Deal Fuels Oncology Ambitions - StocksToTrade
Abcellera Biologics stock hits 52-week high at 6.79 USD - Investing.com UK
AbCellera Biologics, Inc. Actuals & Estimates (NASDAQ:ABCL) - TradingView
ABCL Forecast — Price Target — Prediction for 2027 - TradingView
Jazz Pharmaceuticals (JAZZ) Expands AbCellera Tie Up As Zepzelca Trial Misses Goal - Yahoo Finance
Jazz Pharmaceuticals and AbCellera Biologics Inc. (ABCL) Announce Collaboration - Insider Monkey
12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On - Insider Monkey
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year? - MSN
Abcellera Biologics Inc (ABCL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AbCellera Biologics (ABCL) 2026 Bloom Burton & Co. Healthcare Investor Conference summary - Quartr
앱셀레라바이오로직스 (ABCL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):